Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of X842 (Linaprazan Glurate) in Healthy Subjects
NCT04293965Phase 1Completed
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linaprazan glurate in erosive esophagitis (EE) (4 arms), sponsored by Jiangsu Sinorda Biomedicine Co., Ltd. Primary endpoints: Occurrence and frequency of AEs at 5 weeks, Vital signs of body temperature at 5 weeks and 5 more. Started Oct 2018; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT04293965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293965.